AR032139A1 - Derivados de adamantano, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica, y usos de estos derivados para la fabricacion de medicamentos - Google Patents

Derivados de adamantano, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica, y usos de estos derivados para la fabricacion de medicamentos

Info

Publication number
AR032139A1
AR032139A1 ARP000106417A ARP000106417A AR032139A1 AR 032139 A1 AR032139 A1 AR 032139A1 AR P000106417 A ARP000106417 A AR P000106417A AR P000106417 A ARP000106417 A AR P000106417A AR 032139 A1 AR032139 A1 AR 032139A1
Authority
AR
Argentina
Prior art keywords
group
preparation
pharmaceutical composition
alkyl group
derivatives
Prior art date
Application number
ARP000106417A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR032139A1 publication Critical patent/AR032139A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Abstract

Un derivado de adamantano que tiene la formula general (1), donde: D representa CH2 o CH2CH2; E representa C(O)NH o NHC(O); R1 y R2 cada uno independientemente representa un átomo de hidrogeno o halogeno o un grupo amino, nitro, alquilo C1-6 o trifluormetilo; R3 representa un grupo de formula (2); X representa un átomo de oxígeno o azufre o un grupo NH, SO o SO2; Y representa un átomo de oxígeno o azufre o un grupo NR11, SO o SO2; Z representa un grupo -OH, -SH, -CO2H, alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, -NR6R7, -C(O)NR8R9, imidazolilo, 1-metilimidazolilo, -N(R10)C(O)-alquilo C1-6, alquilcarboniloxi C1-6, alcoxicarboniloxi C1-6, -OC(O)NR12R13, -OCH2OC(O)R14, -OCH2OC(O)OR15 o -OC(O)OCH2OR16; R4 representa un grupo alquilo C2-6; R5 representa un grupo alquilo C1-6; R6, R7, R8, R9, R10, R12 y R13 cada uno independientemente representan un átomo de hidrogeno, o un grupo alquilo C1-6 opcionalmente sustituido con al menos un grupo hidroxilo; R11 representa un átomo de hidrogeno, o un grupo alquilo C1-6 opcionalmente sustituido con al menos un sustituyente independientemente seleccionados de hidroxilo y alcoxi C1-6; y R14, R15 y R16 cada uno, independientemente, un grupo alquilo C1-6; con las condiciones de que (i) cuando E representa NHC(O), X representa O, S o NH e Y representa O, entonces Z representa NR6R7 donde R6 representa un átomo de hidrogeno y R7 representa un átomo de hidrogeno o un grupo alquilo C1-6 sustituido con al menos un grupo hidroxilo, y (ii) cuando E representa NHC(O), X representa O, S o NH, Y representa NH y R5 representa CH2CH2, entonces Z no es -OH o imidazolilo; o una sal o solvato farmacéuticamente aceptable del mismo; proceso para su preparacion, composicion farmacéutica, proceso para la preparacion de la composicion farmacéutica, y usos de estos derivados para la fabricacion de medicamentos.
ARP000106417A 1999-12-09 2000-12-04 Derivados de adamantano, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica, y usos de estos derivados para la fabricacion de medicamentos AR032139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904505A SE9904505D0 (sv) 1999-12-09 1999-12-09 Novel compounds

Publications (1)

Publication Number Publication Date
AR032139A1 true AR032139A1 (es) 2003-10-29

Family

ID=20418060

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106417A AR032139A1 (es) 1999-12-09 2000-12-04 Derivados de adamantano, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica, y usos de estos derivados para la fabricacion de medicamentos

Country Status (27)

Country Link
US (1) US6720452B2 (es)
EP (1) EP1240132B1 (es)
JP (1) JP2003516382A (es)
KR (1) KR20020060991A (es)
CN (1) CN1407968A (es)
AR (1) AR032139A1 (es)
AT (1) ATE263748T1 (es)
AU (1) AU2036301A (es)
BR (1) BR0016227A (es)
CA (1) CA2394236A1 (es)
CO (1) CO5261526A1 (es)
CZ (1) CZ20021982A3 (es)
DE (1) DE60009747T2 (es)
EE (1) EE200200295A (es)
HK (1) HK1046527A1 (es)
HU (1) HUP0300618A3 (es)
IL (1) IL149762A0 (es)
IS (1) IS6405A (es)
MX (1) MXPA02005668A (es)
NO (1) NO20022727L (es)
NZ (1) NZ518985A (es)
PL (1) PL357103A1 (es)
RU (1) RU2002118213A (es)
SE (1) SE9904505D0 (es)
SK (1) SK7622002A3 (es)
WO (1) WO2001042194A1 (es)
ZA (1) ZA200203834B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ATE355273T1 (de) * 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
AU2005258924A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
JP2008504360A (ja) * 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク ヒドロキシル保護された前駆体を脱保護することによる５−［４−（２−ヒドロキシ−プロピル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−１，２，４−トリアジン−２−イル］−ベンズアミド誘導体の製造方法
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
KR100643514B1 (ko) * 2005-05-17 2006-11-23 (주)아모레퍼시픽 히드록시벤조산 아미드 화합물과 그 제조방법 및 이를함유하는 미백화장료 조성물
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
ZA200904477B (en) 2006-11-27 2010-09-29 Lundbeck & Co As H Heteroaryl amide derivatives
RU2010121763A (ru) 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
US8232290B2 (en) 2008-03-25 2012-07-31 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
KR20100053150A (ko) * 2008-11-12 2010-05-20 한국생명공학연구원 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물
PT2243772E (pt) 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e sua utilização
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
MX2014000894A (es) 2011-07-22 2014-02-27 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7.
KR101957843B1 (ko) * 2011-10-06 2019-03-14 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
AR089753A1 (es) 2012-01-20 2014-09-17 Actelion Pharmaceuticals Ltd Derivados de amida heterociclicos como antagonistas del receptor p2x7
EA029644B1 (ru) 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
EP4098650A4 (en) 2020-01-31 2024-03-13 Kumiai Chemical Industry Co 3-ALKOXYBENZOIC ACID AMIDE DERIVATIVE AND PEST CONTROL AGENT

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) 1970-03-03 1973-05-08 Us Army S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
CA2015473C (en) 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
SG52229A1 (en) 1993-08-10 1998-09-28 Black James Foundation Gastrin and cck receptor ligands
JPH10504525A (ja) 1994-05-27 1998-05-06 ジェイムズ・ブラック・ファウンデーション・リミテッド ガストリンとｃｃｋ拮抗薬
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
SK7622002A3 (en) 2003-01-09
NO20022727D0 (no) 2002-06-07
US20020193414A1 (en) 2002-12-19
EP1240132A1 (en) 2002-09-18
KR20020060991A (ko) 2002-07-19
CO5261526A1 (es) 2003-03-31
HUP0300618A3 (en) 2003-12-29
RU2002118213A (ru) 2004-01-10
ZA200203834B (en) 2003-08-14
US6720452B2 (en) 2004-04-13
DE60009747D1 (de) 2004-05-13
EP1240132B1 (en) 2004-04-07
WO2001042194A1 (en) 2001-06-14
NZ518985A (en) 2004-02-27
IS6405A (is) 2002-05-31
CA2394236A1 (en) 2001-06-14
IL149762A0 (en) 2002-11-10
DE60009747T2 (de) 2005-04-28
BR0016227A (pt) 2002-10-01
NO20022727L (no) 2002-07-29
SE9904505D0 (sv) 1999-12-09
EE200200295A (et) 2003-08-15
ATE263748T1 (de) 2004-04-15
JP2003516382A (ja) 2003-05-13
HK1046527A1 (zh) 2003-01-17
CN1407968A (zh) 2003-04-02
CZ20021982A3 (cs) 2003-01-15
AU2036301A (en) 2001-06-18
MXPA02005668A (es) 2002-09-02
HUP0300618A2 (hu) 2003-07-28
PL357103A1 (en) 2004-07-12

Similar Documents

Publication Publication Date Title
AR032139A1 (es) Derivados de adamantano, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica, y usos de estos derivados para la fabricacion de medicamentos
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR029805A1 (es) Compuestos heterociclicos, un proceso para su preparacion , intermediarios, composicion farmaceutica, un proceso para su preparacion, y el uso de dichos compuestos para la fabricacion de un medicamento
AR032361A1 (es) Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
EA199900964A1 (ru) Соли сертралина и лекарственные формы с длительным высвобождением сертралина
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
HUP0104188A2 (hu) Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként
ES2147230T3 (es) Derivados de aminoacidos, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.
AR034556A1 (es) Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado
HUP0100472A2 (hu) Új aminok, mint gyógyászati szerek
CO5261605A1 (es) Compustos farmaceuticos
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
AR035313A1 (es) Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
AR040700A1 (es) Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas
HUP0202501A2 (hu) Pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
DK1414428T3 (da) Histondeacetylaseenzym-inhiberende derivater af hydroxamsyre som hidtil ukendt cytokinsyntese-inhiberende anti-inflammatoriske lægemidler
AR037080A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios
DE59511110D1 (de) Estra-1,3,5(10)-trien-3-sulfamat Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DK1068219T3 (da) Acylerede betulin- og dihydrobetulinderivater samt fremstilling og anvendelse deraf
ATE96431T1 (de) Sulfonamide, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
AR036327A1 (es) Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados
AR004671A1 (es) Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen
AR041769A1 (es) Analogos quimericos de somatostatina-dopamina y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure